- UroToday Home
- Center Of Excellence
Centers of Excellence
Advanced Kidney Cancer
Curated by expert editors: educational forums with videos, abstracts and conference information
Kidney Cancer Legends Take the Stage to Discuss the Role of Cytoreductive Nephrectomy
The 2018 Society of Urologic Oncology (SUO) Meeting was second to none – an outstanding array of speakers and sessions that addressed virtually every salient point pertaining to renal cell carcinoma (RCC) treatment. As you can imagine, cytoreductive nephrectomy was a hot topic for discussion – SUO 2018 marked the first large US
Sumanta (Monty) Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease. Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others.
Library Resources
Evidence based monographs by experts to guide clinical care
Beyond the Abstracts
Author insights on peer reviewed manuscripts
- Biomarker-Based Phase II Trial of Savolitinib in Patients with Advanced Papillary Renal Cell Cancer
- Everolimus versus Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma (ASPEN): a Multicentre, Open-label, Randomised Phase 2 Trial
- Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results from a Randomised, Open-label, Phase 3 Trial
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- MDACC 2018: Promising Emerging Systemic Therapies for mRCC
- MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
- MDACC 2018: Debate: What is the Best Salvage Therapy After Failure of Immune Checkpoint Inhibition?
- MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
- MDACC 2018: Debate: Adjuvant Therapy for Locally Advanced Renal Cell Carcinoma: Is it Ready for Prime Time?
- Axitinib Versus Placebo as an Adjuvant Treatment for Renal Cell Carcinoma: Results From the ATLAS Trial
- Avelumab Plus Axitinib Significantly Improved Progression-Free Survival In Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study
- Exelixis’ Partner Ipsen Announces Health Canada’s Approval of Cabozantinib Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
- Multi-Institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy - Beyond the Abstract
- Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis - Beyond the Abstract
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- Oncologic Outcomes for Open and Laparoscopic Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma – Beyond the Abstract
- Sarcomatoid Renal Cell Carcinoma: Biology and Treatment Advances - Beyond the Abstract
- Impact of Positive Surgical Margins on Overall Survival After Partial Nephrectomy, a Matched Comparison Based on the National Cancer Database - Beyond the Abstract
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma are Associated with Outcome During Pazopanib Therapy in the Metastatic Setting - Beyond the Abstract
- Pazopanib for Metastatic Renal Cell Carcinoma - Beyond the Abstract
- Utilization and Efficacy of Second-line Targeted Therapy in Metastatic Renal Cell Carcinoma - Beyond the Abstract
- U.S. FDA Approves CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- Partial Versus Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes- Beyond the Abstract
- Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis: Beyond the Abstract
Conference Coverage
Recent data from conferences worldwide
CUOS 2019 Kidney Cancer
- CUOS 2019: Cytoreductive Nephrectomy: Is There Still a Role for Nephrectomy in Patients with Metastatic RCC? January 13, 2019
SUO 2018 Kidney Cancer
- SUO 2018: Debate: Enucleo-Resection vs. Wedge Resection for Partial Nephrectomy in 4 cm tumors - CON December 3, 2018
- SUO 2018: Debate: Enucleo-Resection vs. Wedge Resection for Partial Nephrectomy in 4 cm tumors - PRO December 3, 2018
- SUO 2018: There Is Still a Role for Cytoreduction December 1, 2018
- SUO 2018: Neoadjuvant and Adjuvant Therapy: Current Guidelines and Practical Approach for the Urologic Surgeon November 30, 2018
- SUO 2018: Adjuvant Therapies in Kidney Cancer: FDA Panel Insights November 30, 2018
ESMO 2018 Kidney Cancer
- ESMO 2018: COSMIC-021, Phase Ib Study of Cabozantinib in Combination with Atezolizumab and Potent Natural Killer, Myeloid Blood Cell Remodeling by Cabozantinib October 22, 2018
- ESMO 2018: Avelumab + Axitinib vs Sunitinib for the Management of Advanced Renal Cell Carcinoma - JAVELIN Renal 101 October 22, 2018
- ESMO 2018: JAVELIN Renal 101: A Randomized, Phase 3 Study of Avelumab + Axitinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma October 21, 2018
- ESMO 2018: The Current Use of TKI in Renal Cancer October 21, 2018
- ESMO 2018: PD-L1 Status and Clinical Outcomes to Cabozantinib, Sunitinib and Everolimus in Patients with Metastatic Clear-Cell RCC Treated on CABOSUN and METEOR Trials October 20, 2018
- ESMO 2018: The Role of PD-L1 Status as A Predictor or Prognostic Marker of Clinical Outcomes in Patients Treated on CABOSUN and METEOR October 20, 2018
- ESMO 2018: Molecular Correlates Differentiate Response to Atezolizumab plus Bevacizumab vs Sunitinib: Results From a Phase III Study IMmotion151 in Untreated mRCC October 20, 2018
- ESMO 2018: Immunotherapy in Renal and Bladder Cancers October 20, 2018
AUA 2018 Northeastern Section
- NSAUA 2018: Is Radical Nephrectomy Even an Option in the Face of Metastatic Renal Cell Carcinoma? October 13, 2018
FOIU 2018 Kidney Cancer
- FOIU 2018: Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitors Era: The CARMENA Study July 7, 2018
ASCO 2018 Renal Cancer
- ASCO 2018: CABOPRE: Phase II Study of Cabozantinib Prior to Cytoreductive Nephrectomy in Locally Advanced and/or Metastatic Renal Cell Carcinoma June 6, 2018
- ASCO 2018: Prospective, Multinational, Observational Study of Real-World Treatment Outcomes with Pazopanib in Patients with Advanced or Metastatic Renal Cell Carcinoma (Principal Study) June 5, 2018
- ASCO 2018: Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma June 4, 2018
- ASCO 2018: Sunitinib Alone Shows Non-inferiority Versus Standard of Care in mRCC - The CARMENA Study June 3, 2018
- ASCO 2018: CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs. Sunitinib Alone in Metastatic Renal Cell Carcinoma - Results of a Phase III Noninferiority Trial June 3, 2018
- ASCO 2018: A Phase 3, Randomized, Open-label Study of Nivolumab Combined with Cabozantinib vs Sunitinib in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma June 3, 2018
- ASCO 2018: PROSPER: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy June 3, 2018
AUA 2018 Renal Cancer
- AUA 2018: Effect of Ketogenic Diet on the Clear Cell Renal Cell Carcinoma Cell Growth May 29, 2018
- AUA 2018: Effect of African-American Race on Cancer Specific Mortality Differs According to Clear-Cell vs Non-Clear Cell Histologic Subtype in Metastatic Renal Cell Carcinoma May 24, 2018
EAU 2018 Kidney Cancer
ASCO GU 2018 Renal Cancer
- ASCO GU 2018: The CLEAR study: A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-line Treatment of Patients with Metastatic Renal Cell Carcinoma February 14, 2018
- ASCO GU 2018: Incidence and mortality of Renal Cell Carcinoma in the U.S.: A SEER-based Study Investigating Trends Over the Last Four Decades February 13, 2018
- ASCO GU 2018: Outcomes of Metastatic Chromophobe Renal Cell Carcinoma with Sarcomatoid Features February 12, 2018
- ASCO GU 2018: The Future of Immuno-Oncology in Renal Cell Carcinoma February 12, 2018
- ASCO GU 2018: Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: Past, Present, and Future February 12, 2018
- ASCO GU 2018: Phase III Trial of Adjuvant Sunitinib in Patients with High-risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis February 12, 2018
- ASCO GU 2018: IMmotion 151: A randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma February 12, 2018
- ASCO GU 2018: Status of Adjuvant Therapy in Renal Cell Carcinoma in 2018: Completed Trials and What Is Being Tested? February 11, 2018
ESMO 2017 Kidney Cancer
- ESMO 2017: A Change of Paradigm in First-Line Treatment of Metastatic Renal Cell Carcinoma? September 11, 2017
- ESMO 2017: CheckMate 214: Efficacy and safety of Nivolumab + Ipilimumab vs Sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups September 11, 2017
- ESMO 2017: KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma September 11, 2017
ASCO 2017 Renal Cancer
ASCO GU 2017 Kidney Cancer
- ASCO GU 2017: A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). - Session Highlights February 18, 2017
- ASCO GU 2017: Adjuvant Therapy of Renal Cell Carcinoma: Current Controversies - Session Highlights February 18, 2017
- ASCO GU 2017: Phase II Study Supports Potential For Genentech’s TECENTRIQ® (ATEZOLIZUMAB) PLUS AVASTIN® (BEVACIZUMAB) For People With Locally Advanced or Metastatic Renal Cell Carcinoma - Session Highlights February 18, 2017
- ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Urologic Oncology - Session Highlights February 18, 2017
@UroToday
E-Newsletters
Free Daily and Weekly newsletters offered by content of interest
The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.